In Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. No. 13-854, (January 20, 2015), the Supreme Court held that while the ultimate question of claim construction remains a legal question subject to de novo review, the district court’s subsidiary fact determinations … Continue reading Subsidiary Facts Underlying a District Court’s Claim Construction are Reviewed for Clear Error, but De Novo Review Survives for Most Cases